Comparing UnitedHealth Group With Industry Competitors In Health Care Providers & Services Industry

In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating UnitedHealth Group UNH against its key competitors in the Health Care Providers & Services industry. By analyzing important financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.

UnitedHealth Group Background

UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 53 million members globally, including 5 million outside the U.S. as of mid-2023. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.

Company P/E P/B P/S ROE EBITDA (in billions) Gross Profit (in billions) Revenue Growth
UnitedHealth Group Inc 31.24 5.43 1.26 -1.61% $1.84 $23.0 8.56%
Centene Corp 15.22 1.53 0.27 4.41% $1.96 $4.64 3.9%
Molina Healthcare Inc 19.13 4.59 0.57 6.91% $0.47 $1.22 21.87%
HealthEquity Inc 120.88 3.28 6.73 1.31% $0.08 $0.17 12.21%
Progyny Inc 44.92 4.56 2.49 3.0% $0.02 $0.06 7.62%
Average 50.04 3.49 2.52 3.91% $0.63 $1.52 11.4%

By thoroughly analyzing UnitedHealth Group, we can discern the following trends:

  • A Price to Earnings ratio of 31.24 significantly below the industry average by 0.62x suggests undervaluation. This can make the stock appealing for those seeking growth.

  • It could be trading at a premium in relation to its book value, as indicated by its Price to Book ratio of 5.43 which exceeds the industry average by 1.56x.

  • With a relatively low Price to Sales ratio of 1.26, which is 0.5x the industry average, the stock might be considered undervalued based on sales performance.

  • The company has a lower Return on Equity (ROE) of -1.61%, which is 5.52% below the industry average. This indicates potential inefficiency in utilizing equity to generate profits, which could be attributed to various factors.

  • The company exhibits higher Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $1.84 Billion, which is 2.92x above the industry average, implying stronger profitability and robust cash flow generation.

  • The gross profit of $23.0 Billion is 15.13x above that of its industry, highlighting stronger profitability and higher earnings from its core operations.

  • The company's revenue growth of 8.56% is significantly lower compared to the industry average of 11.4%. This indicates a potential fall in the company's sales performance.

Debt To Equity Ratio

The debt-to-equity (D/E) ratio is an important measure to assess the financial structure and risk profile of a company.

Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.

When evaluating UnitedHealth Group alongside its top 4 peers in terms of the Debt-to-Equity ratio, the following insights arise:

  • UnitedHealth Group has a higher debt-to-equity ratio of 0.85 compared to its top 4 peers.

  • This indicates a higher level of financial risk as the company relies more heavily on borrowed funds. Investors may perceive this as a potential concern.

Key Takeaways

For UnitedHealth Group, the PE ratio is low compared to peers, indicating potential undervaluation. The PB ratio is high, suggesting investors are willing to pay a premium for its assets. The PS ratio is low, indicating a potential bargain based on revenue. The low ROE suggests lower profitability compared to peers, while high EBITDA and gross profit indicate strong operational performance. The low revenue growth may be a concern for future prospects in the Health Care Providers & Services industry.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Posted In: NewsMarketsTrading IdeasBZI-IA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!